Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 12 小时前评分70
正文 · 原文
ASTRIDE:🫁
Serplulimab + chemotherapy showed a numerical OS advantage over atezolizumab + chemotherapy in 1L ES-SCLC (12.4 vs 10.2 months; HR 0.82).
@OncoAlert #ESMO26 #LungCancer #ESMOAmbassadors #Lcsm #ESMOcommunity @myESMO
51 浏览 · 5 赞 · 3 转发 · 1 回复
会议摘要
帖内回复
- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@OncoAlert @myESMO 📊 Despite higher 2 year OS (32.2% vs 17.6%), the nearly identical PFS (HR 0.95) makes the survival signal difficult to interpret.
来源：Aya Mohamed | MSc, MD 🎗 · x.com